Aligos Q3 net loss $18.6M, cash $142.3M; HBV and NASH programs advancing

Aligos Therapeutics, Inc.

2022-Q3 EPS reported -$1.74

Net loss $18.6M ($0.44 per share) vs $33.1M ($0.78) a year ago; R&D spending fell to $17.8M.
Cash, equivalents, and investments $142.3M as of Sep 30, 2022, down from $205.8M at Dec 31, 2021.
HBV CAM ALG-000184 initiated up-to-48-week dosing; siRNA ALG-125755 SAD in healthy volunteers ongoing.
NASH THR-beta agonist ALG-055009 MAD data to be presented at AASLD; plans to advance to Phase 2.
Pan-coronavirus protease inhibitor ALG-097558 entering Phase 1 enabling studies; clinical eval expected Q2 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Aligos Therapeutics, Inc. reported third quarter, September 30, 2022 results: net income Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common sh, EPS $(0.44).

Period: third quarter, September 30, 2022
Net income: Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common sh
EPS: $(0.44)
Result: reported results

Exact text from the filing

Net losses for the three months ended September 30, 2022, were $18.6 million or basic and diluted net loss per common share of $(0.44), compared to net losses of $33.1 million or basic and diluted net loss per common share of $(0.78) for the three months ended September 30, 2021.

View on SEC.gov

Browse all earnings releases →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-22-007002

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.